|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chemotherapy for gastric cancer显示文摘变形胃的癌症仍然是非药品疾病。没有生活妥协的质量,辩解的化疗被表明了延长幸存。单个代理人的许多和联合被证实了在变形疾病的治疗活跃。客观反应率为综合化学疗法为单个代理人的治疗和 30-60% 从 10-30%。阶段 II 和 III 研究的结果在这篇论文以及新药的潜在的功效被考察。为有局部性的疾病的病人,助手和 neoadjuvant 化疗和放射治疗的角色被讨论。辅助化疗上的大多数研究没能表明一个幸存优点,因此,它没在大多数中心被看作标准疗法。辅助免疫化疗在朝鲜和日本根本上被开发了。有 OK-432 的阶段 III 试用的元分析建议那免疫化疗可以改进病人的幸存与 curatively resected 胃的癌症。基于美国的结果团体之间 0116 学习,手术后的 chemoradiation 与 resected 在病人作为标准照顾被接受了在北美洲的胃的癌症。然而,结果被病人们经历了的事实有点惊讶不到推荐 D1 淋巴节点解剖和复发的模式建议没有任何效果,积极效果在微变形疾病上源于本地放射疗法。Neoadjuvant 化疗或 chemoradiation 治疗仍然保持试验性,但是几阶段 II 学习正在显示出有希望的结果。阶段 III 试用被需要。 | Javier Sastre Jose Angel García-Saenz Eduardo Díaz-Rubio | 2006 | World Journal of Gastroenterology2006，12，2： | 22 |
| 2 | Role of cetuximab in first-line treatment of metastatic colorectal cancer显示文摘The treatment of metastatic colorectal cancer(mCRC)has evolved considerably in the last decade,currently allowing most mCRC patients to live more than two years.Monoclonal antibodies targeting the epidermal growth factor receptor(EGFR)and vascular endothelial growth factor play an important role in the current treatment of these patients.However,only antibodies directed against EGFR have a predictive marker of response,which is the mutation status of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog(KRAS).Cetuximab has been shown to be effective in patients with KRAS wild-type mCRC.The CRYSTAL study showed that adding cetuximab to FOLFIRI(regimen of irinotecan,infusional fluorouracil and leucovorin)significantly improved results in the first-line treatment of KRAS wildtype mCRC.However,results that evaluate the efficacy of cetuximab in combination with oxaliplatin-based chemotherapy in this setting are contradictory.On the other hand,recent advances in the management of colorectal liver metastases have improved survival in these patients.Adding cetuximab to standard chemotherapy increases the response rate in patients with wild-type KRAS and can thus increase the resectability rate of liver metastases in this group of patients.In this paper we review the different studies assessing the efficacy of cetuximab in the first-line treatment of mCRC. | Miguel Jhonatan Sotelo Beatriz García-Paredes Carlos Aguado Javier Sastre Eduardo Díaz-Rubio | 2014 | World Journal of Gastroenterology2014，20，15： | 7 |
| 3 | Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?显示文摘Fluoropyrimidines play a central role in the first-line treatment of metastatic colorectal cancer.Our aim was to review whether capecitabine was a safer,non-inferior,economically superior and more convenient alternative to 5-fluorouracil.Capecitabine has previously been compared to 5-fluorouracil-either as a monotherapy or in combination with oxaliplatin,irinotecan,or biological drugs-and has been found to have comparable efficacy and safety profiles.Furthermore,pharmacoeconomic data and patients’preferences for oral chemotherapy further favor capecitabine.Therefore,capecitabine appears to be an effective and safe alternative to fluorouracil in the first-line treatment of metastatic colorectal cancer. | Carlos Aguado Beatriz García-Paredes Miguel Jhonatan Sotelo Javier Sastre Eduardo Díaz-Rubio | 2014 | World Journal of Gastroenterology2014，20，20： | 4 |
| 4 | First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)显示文摘 | J. Sastre E. Aranda C. Grávalos B. Massutí M. Varella-Garcia F. Rivera G. Soler A. Carrato J.L. Manzano E. Díaz-Rubio M. Hidalgo | 2009 | Critical Reviews in Oncology and Hematology2009，，1： | 2 |
| 5 | Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function显示文摘 | Jon Zugazagoitia Aránzazu Manzano Javier Sastre Jose María Ladero Javier Puente Eduardo Díaz-Rubio | 2013 | Clinical and Translational Oncology2013，，2： | 2 |
| 6 | Modeling of substitutionin SAPO-5 and SAPO-34 molecular sieves 显示文摘 | Sastre G Lewis D W Catlolw C R | 1997 | Journal of Physical Chenistry1997，101，27： | 1 |
| 7 | Proealeitonin is not sufficiently reliable to be the sole marker of neonatal sepsis of no-soeomial origin显示文摘 | Lopez Sastre JB Perez Solis D Roques Serradilla V | 2006 | BMC Pediatr2006，6，： | 1 |
| 8 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome显示文摘 | Caronia D Martin M Sastre J | 2011 | Clin Cancer Res2011，17，7： | 1 |
| 9 | Characterisation of the deactivation of platinum and palladium supported on activated carbon used as hydrodechlorination catalysts显示文摘 | Salvador Ordo &ez Fernando D'iez V Herminio Sastre | 2001 | Applied Catalysis B: Environmental2001，31，： | 1 |
| 10 | Magnetic field exposure and cardiovascular disease mortality among electric utility workers 显示文摘 | SAVITZ D A LIAO D SASTRE A | 1999 | Am J Epidemiol1999，149，2： | 1 |
| 11 | Enhanced CD8 + T cell response to HIV - 1 env by combined immunization with influenza and vaccinia virus recombinants 显示文摘 | Gonzalo RM Rodrfguez D Garcia- Sastre A | 1999 | Vaccine1999，17，78： | 1 |
| 12 | Metabolism of agmatine in macrophages:modulation by lipopolysaccharide and inhibitory cytokines显示文摘 | Sastre M Galea E Feinstein D | 1998 | J Biochem1998，330，3： | 1 |
| 13 | Continuation of bevacizumab af- ter first progression in metastatic coloreetaleancer( ML18147 ) : a ran- domised phase 3 trial显示文摘 | Bennouna J Sastre J Arnold D | 2013 | Lancet Onco12013，14，1： | 1 |
| 14 | Procalction is not sufficiently reliable to be the sole marker of neonatal sepsis of nosocomial origin显示文摘 | Lopez Sastre J B Perez Solt s D Roques Serradilla V | 2006 | BMC Pediatr2006，18，6： | 1 |
| 15 | Sustained release of bupivacaine from devices based on chitosan显示文摘 | Bernardo M V Blanco M D Sastre R Let aI | 2003 | Farmaco2003，58，11： | 1 |
| 16 | Magnetic field exposure and cardiovascular disease mortality among electric utility workers 显示文摘 | Savitz DA Liao D Sastre A | 1999 | Am J Epidemiol1999，149，2： | 1 |
| 17 | Magnetic field exposure and cardiovascular disease mortality among electric utility workers显示文摘 | SAVITZ D A LIAO D SASTRE A | 1999 | Am J Epidemiol1999，149，2： | 1 |
| 18 | Irinotecan in the treatment of elderly patients with advanced colorectal cancer显示文摘 | Javier Sastre Javier Puente Jose A. García-Saenz Eduardo Díaz-Rubio | 2008 | Critical Reviews in Oncology and Hematology2008，，3： | 1 |
| 19 | Continuation of bevacizumab af- ter first progression in metattatic colorectal cancer (ML18147) : a ran- domised phase 3 trim 显示文摘 | Bennouna J Sastre J Arnold D | 2013 | i Lancet Oncol2013，14，1： | 1 |
| 20 | Selective synthesis of glycerol monolaurate with zeolitic molecular sieves 显示文摘 | Machado M D Perez P J Sastre E | 2000 | Applied Catalysis A: General2000，203，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员